Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 11/396,328, filed Mar 31, 2006. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,024,282 | Method for Reliable Classification of Samples in Clinical Diagnostics Using an Improved Method of Classification In force · High confidence | Biodesix Inc. | In force | High confidence | ||
| US 7,736,905 | Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease In force · High confidence | Biodesix, Inc., a Delaware Corporation | In force | High confidence | ||
| US 9,152,758 | Method and system for determining whether a drug will be effective on a patient with a disease In force · High confidence | Biodesix Inc. | In force | High confidence | ||
| US 7,858,390 | Selection of Colorectal Cancer Patients for Treatment with Drugs Targeting Egfr Pathway Lapsed Dec 28, 2022 on the fee record Ended Dec 28, 2022 · Medium confidence | Biodesix Inc. | Lapsed Dec 28, 2022 on the fee record | Ended Dec 28, 2022 | Medium confidence | |
| US 7,867,775 | Selection of Head and Neck Cancer Patients for Treatment with Drugs Targeting Egfr Pathway Term ended Term ended Mar 31, 2026 · High confidence | Biodesix Inc. | Term ended | Term ended Mar 31, 2026 | High confidence | |
| US 7,879,620 | Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease Term ended Term ended Mar 31, 2026 · High confidence | Biodesix Inc. | Term ended | Term ended Mar 31, 2026 | High confidence | |
| US 8,097,469 | Method and System for Determining Whether a Drug Will Be Effective on a Patient with a Disease Term ended Term ended Mar 31, 2026 · High confidence | Biodesix Inc. | Term ended | Term ended Mar 31, 2026 | High confidence | |
| US 8,119,417 | Monitoring Treatment of Head and Neck Cancer Patients with Drugs Egfr Pathway Using Mass Spectrometry of Patient Samples Term ended Ended no later than Mar 31, 2026 · Medium confidence | Biodesix Inc. | Term ended | Ended no later than Mar 31, 2026 | Medium confidence | |
| US 8,119,418 | Monitoring Treatment of Colorectal Cancer Patients with Drugs Targeting Egfr Pathway Using Mass Spectrometry of Patient Samples Term ended Ended no later than Mar 31, 2026 · Medium confidence | Biodesix Inc. | Term ended | Ended no later than Mar 31, 2026 | Medium confidence | |
| US 8,586,379 | Monitoring treatment of colorectal cancer patients with drugs targeting EGFR pathway using mass spectrometry of patient samples Term ended Ended no later than Mar 31, 2026 · Medium confidence | Biodesix Inc. | Term ended | Ended no later than Mar 31, 2026 | Medium confidence | |
| 4 more patents in this group · Pro | ||||||
10 of 14 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
Pro members see all 14, including 11 expired and 2 expiring within the 18 months from Nov 16, 2026.
3 of these are in force and held by Biodesix, Inc..
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.